Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, July 24, 2014
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
NIST Instrument Enables High-speed Chemical Imaging of Tissues
Researchers have demonstrated a dramatically improved technique for analyzing biological cells and tissues based on characteristic molecular vibration "signatures."
Transplanting Gene into Injured Hearts Creates Biological Pacemakers
Researchers develop first minimally invasive gene therapy procedure to treat heart rhythm disorders by transforming ordinary heart muscle cells into specialized rhythm-keeping cells, potentially eliminating future need for electronic pacemakers.
Common Gene Variants Account for Most Genetic Risk for Autism
Roles of heritability, mutations, environment estimated - NIH-funded study.
Using LC-MS to Analyse Sulfonamides in Food Grade Honey
Sulfonamides are one of a number of groups of chemicals whose presence in honey is limited by international regulations.
ChIP Sequencing Kit for Next Generation Sequencing
The assay kit from Porvair Sciences extends the benefits of their proprietary Chromatrap® solid state ChIP technology.
Illumina's HiSeq X Ten Sequencing Technology for Population Studies
Next-generation sequencing technologies to be implemented at new High-Throughput Genomics Center for the MENA region.
Foodborne Pathogen Detection Speeds Up Dramatically
Next-generation sequencing techniques allow rapidly identification of strains of salmonella, quickening responses to potential outbreaks.
Bowel Cancer Breakthrough May Benefit Thousands of Patients
Researchers at Queen’s University have discovered how two genes cause bowel cancer cells to become resistant to treatments used against the disease.
Innovative Technology Enables First Crystal Structure of mGlu5 Transmembrane Domain to be Determined
Several novel drug candidates have been identified to help treat specific neuropsychiatric disorders.
NIH Scientists Identify Gene Linked to Fatal Inflammatory Disease in Children
Repurposed drugs may offer first potential therapy.
Scroll Up
Scroll Down
Return
Therapeutic Targeting of Neuroendocrine Tumours Utilising microRNAs
Stan Sidhu, University of Sydney, speaking at Genomics Research Europe 2012
Date Posted: Friday, February 01, 2013
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG
Company will undertake a target discovery project for an undisclosed disease indication.
Tuesday, May 06, 2014
Cenix BioScience Joins EU FP7 Consortium for Discovery of miRNA Medicines
Company has joined an EU-funded consortium focused on the discovery of microRNA medicines in the area of cardiac and inflammatory metabolic diseases.
Wednesday, August 14, 2013
Cenix BioScience Expands Operations to U.S.
Company establishes new subsidiary named Cenix BioScience USA in Minnesota.
Friday, March 02, 2012
Cenix signs RNAi research agreement with SYGNIS
Cenix BioScience GmbH, announced it has signed a research agreement with SYGNIS Bioscience GmbH & Co. KG, a pharmaceutical company dedicated to developing innovative therapies for the treatment of disorders of the central nervous system.
Thursday, November 17, 2011
Cenix BioScience Signs Collaboration and Technology License Agreement for In Vivo siRNA Delivery
Collaboration and Technology License Agreement to improve the in vivo applicability of siRNA-based experimentation, focusing on the further co-development of DARE™.
Thursday, May 05, 2011
Cenix BioScience Joins EU FP7 Consortium
Consortium focused on improving the in vivo use of siRNA technology in the area of respiratory and inflammatory diseases.
Wednesday, March 30, 2011
Cenix BioScience Grows, Establishing New R&D Subsidiary in Flanders, Belgium
The new company accelerates the development of the company’s R&D capabilities in key growth areas including CNS-focused drug discovery and in vivo RNAi.
Saturday, January 15, 2011
Cenix BioScience Expands Relationship with AstraZeneca, Signing Multi-Project Research Agreement
The new agreement calls for Cenix to complete three major projects applying same platform for RNAi-based research.
Friday, June 26, 2009
Cenix BioScience Signs Multi-Project Research Agreement with AstraZeneca
The agreement expands relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications.
Tuesday, June 16, 2009
InteRNA Technologies and Cenix BioScience Ink Research Agreement for miRNA Drug Discovery
The research agreement comprises functional screens in human cell lines using InteRNA’s proprietary library of miRNAs.
Tuesday, November 18, 2008
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv